DE69626393D1 - Spezifische oligonukleotide für hepatitis b virus - Google Patents
Spezifische oligonukleotide für hepatitis b virusInfo
- Publication number
- DE69626393D1 DE69626393D1 DE69626393T DE69626393T DE69626393D1 DE 69626393 D1 DE69626393 D1 DE 69626393D1 DE 69626393 T DE69626393 T DE 69626393T DE 69626393 T DE69626393 T DE 69626393T DE 69626393 D1 DE69626393 D1 DE 69626393D1
- Authority
- DE
- Germany
- Prior art keywords
- oligonucleotids
- hepatitis
- virus
- specific
- hbv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700721 Hepatitis B virus Species 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46739795A | 1995-06-06 | 1995-06-06 | |
| PCT/EP1996/002432 WO1996039502A1 (en) | 1995-06-06 | 1996-06-04 | Oligonucleotides specific for hepatitis b virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69626393D1 true DE69626393D1 (de) | 2003-04-03 |
| DE69626393T2 DE69626393T2 (de) | 2003-12-04 |
Family
ID=23855522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69626393T Expired - Lifetime DE69626393T2 (de) | 1995-06-06 | 1996-06-04 | Spezifische oligonukleotide für hepatitis b virus |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US5856459A (de) |
| EP (1) | EP0832211B1 (de) |
| AT (1) | ATE233318T1 (de) |
| AU (1) | AU6125296A (de) |
| CA (1) | CA2226458A1 (de) |
| DE (1) | DE69626393T2 (de) |
| DK (1) | DK0832211T3 (de) |
| ES (1) | ES2188760T3 (de) |
| WO (1) | WO1996039502A1 (de) |
| ZA (1) | ZA964445B (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040054156A1 (en) * | 1992-05-14 | 2004-03-18 | Kenneth Draper | Method and reagent for inhibiting hepatitis B viral replication |
| WO2002081494A1 (en) * | 2001-03-26 | 2002-10-17 | Sirna Therapeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| US5646262A (en) * | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
| US5985662A (en) * | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
| WO1998018818A2 (en) | 1996-10-31 | 1998-05-07 | Biogen, Inc. | Hepatitis b inhibitors |
| CN1057302C (zh) * | 1997-08-27 | 2000-10-11 | 中国科学院上海生物化学研究所 | 抑制乙型肝炎病毒复制的反义脱氧寡核苷酸 |
| CN1215058A (zh) | 1997-10-21 | 1999-04-28 | 中国科学院上海生物化学研究所 | 新的三链形成寡核苷酸结构及其在抗乙肝病毒中的应用 |
| PL348766A1 (en) | 1998-12-04 | 2002-06-03 | Biogen | Hbv core antigen particles with multiple immunogenic components attached via peptide ligands |
| WO2001064959A1 (en) * | 2000-03-02 | 2001-09-07 | Akzo Nobel N.V. | Detection of hepatitis b virus rna |
| US6583279B1 (en) | 2001-01-26 | 2003-06-24 | Becton, Dickinson And Company | Sequences and methods for detection of hepatitis B virus |
| JP2005525991A (ja) * | 2001-05-16 | 2005-09-02 | マイジェニックス インコーポレイテッド | 核酸ベースの化合物およびその使用方法 |
| US20030140362A1 (en) * | 2001-06-08 | 2003-07-24 | Dennis Macejak | In vivo models for screening inhibitors of hepatitis B virus |
| ATE519861T1 (de) * | 2002-06-14 | 2011-08-15 | Gen Probe Inc | Zusammensetzungen zum nachweis von hepatitis-b- virus |
| EP1403385A1 (de) * | 2002-09-27 | 2004-03-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methode zur Darstellung der Replikation von HBV und zum Testen der Sensibilität von Wirkstoffen |
| MXPA05004588A (es) * | 2002-10-29 | 2005-12-14 | Coley Pharmaceutical Group Ltd | Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c. |
| AU2010306639B2 (en) | 2009-10-16 | 2017-02-16 | Glaxo Group Limited | HBV antisense inhibitors |
| SI3505528T1 (sl) * | 2011-04-21 | 2021-04-30 | Glaxo Group Limited | Modulacija izražanja virusa hepatitisa B (HBV) |
| PT2726613T (pt) * | 2011-06-30 | 2018-10-26 | Arrowhead Pharmaceuticals Inc | Composições e métodos para inibição da expressão de genes do vírus da hepatite b |
| GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| CA2991639A1 (en) | 2015-08-07 | 2017-02-16 | Arrowhead Pharmaceuticals, Inc. | Rnai therapy for hepatitis b virus infection |
| JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
| WO2019240503A1 (ko) * | 2018-06-12 | 2019-12-19 | 주식회사 에이엠사이언스 | B형 간염 예방 또는 치료용 조성물 |
| WO2019240504A1 (en) * | 2018-06-12 | 2019-12-19 | Am Sciences Co., Ltd. | Modified oligonucleotides for inhibition of target gene expression |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225326A (en) * | 1988-08-31 | 1993-07-06 | Research Development Foundation | One step in situ hybridization assay |
| US5610050A (en) * | 1990-04-20 | 1997-03-11 | The General Hospital Corporation | Methods of preventing viral replication |
| AU662304B2 (en) * | 1990-10-22 | 1995-08-31 | Fox Chase Cancer Center | DNA construct for providing RNA therapy |
| JPH07500820A (ja) * | 1991-09-05 | 1995-01-26 | ユニバーシティ オブ コネティカット | ポリヌクレオチド又はオリゴヌクレオチドの細胞への標的を定めた送達 |
| US5585479A (en) * | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
| EP0751949A4 (de) * | 1993-12-23 | 1997-08-20 | Apollon Inc | Virale anti-hepatitis b oligonukleotide |
| US5728518A (en) * | 1994-01-12 | 1998-03-17 | The Immune Response Corporation | Antiviral poly-and oligonucleotides |
| US5646262A (en) * | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
-
1995
- 1995-06-06 US US08/468,352 patent/US5856459A/en not_active Expired - Lifetime
-
1996
- 1996-05-30 ZA ZA964445A patent/ZA964445B/xx unknown
- 1996-06-04 DK DK96918671T patent/DK0832211T3/da active
- 1996-06-04 ES ES96918671T patent/ES2188760T3/es not_active Expired - Lifetime
- 1996-06-04 EP EP96918671A patent/EP0832211B1/de not_active Expired - Lifetime
- 1996-06-04 AU AU61252/96A patent/AU6125296A/en not_active Abandoned
- 1996-06-04 CA CA002226458A patent/CA2226458A1/en not_active Abandoned
- 1996-06-04 WO PCT/EP1996/002432 patent/WO1996039502A1/en active IP Right Grant
- 1996-06-04 DE DE69626393T patent/DE69626393T2/de not_active Expired - Lifetime
- 1996-06-04 AT AT96918671T patent/ATE233318T1/de not_active IP Right Cessation
-
1997
- 1997-07-28 US US08/901,612 patent/US6984729B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2226458A1 (en) | 1996-12-12 |
| US5856459A (en) | 1999-01-05 |
| AU6125296A (en) | 1996-12-24 |
| US6984729B1 (en) | 2006-01-10 |
| DE69626393T2 (de) | 2003-12-04 |
| ATE233318T1 (de) | 2003-03-15 |
| ES2188760T3 (es) | 2003-07-01 |
| EP0832211B1 (de) | 2003-02-26 |
| EP0832211A1 (de) | 1998-04-01 |
| ZA964445B (en) | 1996-12-06 |
| WO1996039502A1 (en) | 1996-12-12 |
| DK0832211T3 (da) | 2003-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69626393T2 (de) | Spezifische oligonukleotide für hepatitis b virus | |
| DE69403642D1 (de) | 7-deazapurin modifizierte oligonukleotide | |
| DE69829115D1 (de) | Zusammensetzungen und verfahren zur behandlung von hepatitis c virus-bedingten erkrankungen | |
| DE69330372T2 (de) | ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN | |
| BR9502707A (pt) | Composto composição farmacêutica e método para o tratamento de uma afecção | |
| ATE421883T1 (de) | Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline | |
| DE69803391D1 (de) | Zusammensetzung die mindestens ein doppel strangiges rna und mindestens ein interferon enthält, zur behandlung von virale hepatitis | |
| NO983716L (no) | Metoksyetoksy oligonukleotider for modulering av protein-kinase C ekspresjon | |
| DE69710077T2 (de) | Verfahren zur erkennung von verbindungen, die die interaktion von rna und rna-bindeproteinen beeinflussen | |
| DE60137631D1 (de) | Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen | |
| ATE298741T1 (de) | Polyaromatische verbindungen zur behandlung von herpes-infektionen | |
| DK1123414T3 (da) | Antisense-modulering af integrin alpha 4.ekspression | |
| DE60015568D1 (de) | Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür | |
| ES2091928T3 (es) | Metodos de prevencion de la replicacion virica. | |
| EP1331267A3 (de) | Spezifische Oligonukleotide für Hepatitis C-Virus | |
| DK0877758T3 (da) | Oprenset SR-p70-protein | |
| ATE369429T1 (de) | Strukturproteine des virus, welches die pankreas- krankheit bei fischen verursacht, und ihre verwendungen | |
| WO1996039501A3 (en) | Oligonucleotides specific for human papillomavirus | |
| DE69922364D1 (de) | Verfahren zur immunisierung und behandlung von h. pylori infektion | |
| FR2679235B1 (fr) | Methode de purification des aminoacides, des acides nucleiques et de leurs derives. | |
| EA199700438A1 (ru) | Межгенные участки вируса верхушки банановой грозди | |
| ATE493408T1 (de) | Antiinfektiöse mittel | |
| HU9300349D0 (en) | Method for producing dibenzo- or benzo-pyrido-cyclohepta-piperidine derivatives or piperidylidene or piperazine derivatives thereof as well as pharmaceutical preparatives contqining them | |
| ATE212839T1 (de) | Hämoregulatorische verbindungen | |
| ATE55257T1 (de) | Verfahren zur herstellung von hochgereinigten, hepatitis-b-virus-infektionsfreien gammaglobulinen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |